Asset / Drug

Keytruda

Drug and asset intelligence for Keytruda with 30 indexed intelligence signals across regulatory, clinical, competitive, and market developments.

Signals: 13
Catalysts: 17
Stage: Approved

Sponsor company

Merck →

Mechanism of action

KRAS G12C Inhibitor

Recent signals(13)

ClinicalJune 18, 2026

Study Evaluates ePRO Follow-Up for Oncology Patients Post-Hospitalization

The study assesses the feasibility of using electronic patient-reported outcomes (ePRO) and transitional nurse consultations for oncology patients post-discharge.

ClinicalJune 18, 2026

ComboMATCH Trial Targets Genetic Mutations in Advanced Solid Tumors

The ComboMATCH trial aims to match patients with advanced solid tumors to targeted therapies based on genetic testing.

RegulatoryJune 17, 2026

FDA Draft Guidance Aims to Reduce Animal Testing for Cancer Drugs

The FDA has issued draft guidance to minimize unnecessary animal testing in the development of cancer drugs.

ClinicalJune 17, 2026

Lactylation-related biomarker predicts prognosis and therapy response in cutaneous melanoma

A novel lactylation-related prognostic model (CM-LP11) effectively stratifies cutaneous melanoma patients into high- and low-risk groups based on overall survival.

ClinicalJune 17, 2026

Study Reveals Risk Factors for Second Primary Cancer in Colorectal Cancer Survivors

The study identifies age, neoadjuvant therapy, and tumor characteristics as risk factors for second primary cancer in colorectal cancer survivors.

ClinicalJune 17, 2026

Gene Amplification Adjacent to F3 Linked to Poor Outcomes in Pancreatic Adenocarcinoma

Amplification of ARHGAP29 and SLC44A3 genes adjacent to F3 is associated with worse overall and disease-free survival in pancreatic adenocarcinoma.

RegulatoryJune 17, 2026

FDA Grants Priority Review for KEYTRUDA and KEYTRUDA QLEX in MIBC Treatment

The FDA has granted priority review for KEYTRUDA and KEYTRUDA QLEX in combination with Padcev for muscle-invasive bladder cancer.

ClinicalJune 17, 2026

Merck and Eisai's LITESPARK-012 Trial Fails to Meet Primary Endpoints in RCC

The Phase 3 LITESPARK-012 trial did not meet its dual primary endpoints of progression-free survival and overall survival for the evaluated combination therapies.

RegulatoryJune 16, 2026

FDA Grants Breakthrough Therapy Designation for Calderasib in KRAS G12C-Mutant NSCLC

Calderasib (MK-1084) received Breakthrough Therapy designation for first-line treatment of KRAS G12C-mutant NSCLC.

CompetitiveJune 16, 2026

Merck Reports Promising Long-Term Data for KEYTRUDA and Intismeran in Oncology at ASCO 2026

Five-year follow-up data from KEYNOTE-942 show the potential of intismeran autogene in combination with KEYTRUDA for high-risk melanoma. Additionally, KEYNOTE-522 results indicate a continued survival benefit for high-risk early-stage TNBC patients.

ClinicalJune 16, 2026

5-Year Data Shows Intismeran Autogene + KEYTRUDA Reduces Melanoma Recurrence Risk by 49%

Intismeran autogene in combination with KEYTRUDA demonstrated a 49% reduction in the risk of recurrence or death in high-risk melanoma patients.

RegulatoryJune 16, 2026

Merck's KEYTRUDA Plus Padcev Receives Positive EU CHMP Opinion for Muscle-Invasive Bladder Cancer

The EU CHMP has issued a positive opinion for the combination of KEYTRUDA and Padcev as a treatment for cisplatin-ineligible muscle-invasive bladder cancer.

RegulatoryJune 13, 2026

FDA Approves KEYTRUDA Combinations for Adjuvant Treatment in Clear Cell RCC

The FDA has approved KEYTRUDA and KEYTRUDA QLEX in combination with WELIREG for adjuvant treatment in ccRCC patients, marking a significant advancement in therapy.

Upcoming milestones(1)

Label Expansion

Merck — Keytruda

Further label stacking extends Keytruda lifecycle amid biosimilar horizon.

July 22, 2026 · Approved

Related catalysts(17)

Label Expansion

Merck — Keytruda

Further label stacking extends Keytruda lifecycle amid biosimilar horizon.

July 22, 2026 · Approved

Topline Data

Sponsor company

Mechanism of action

Recent signals(13)

Study Evaluates ePRO Follow-Up for Oncology Patients Post-Hospitalization

ComboMATCH Trial Targets Genetic Mutations in Advanced Solid Tumors

FDA Draft Guidance Aims to Reduce Animal Testing for Cancer Drugs

Lactylation-related biomarker predicts prognosis and therapy response in cutaneous melanoma

Study Reveals Risk Factors for Second Primary Cancer in Colorectal Cancer Survivors

Gene Amplification Adjacent to F3 Linked to Poor Outcomes in Pancreatic Adenocarcinoma

FDA Grants Priority Review for KEYTRUDA and KEYTRUDA QLEX in MIBC Treatment

Merck and Eisai's LITESPARK-012 Trial Fails to Meet Primary Endpoints in RCC

FDA Grants Breakthrough Therapy Designation for Calderasib in KRAS G12C-Mutant NSCLC

Merck Reports Promising Long-Term Data for KEYTRUDA and Intismeran in Oncology at ASCO 2026

5-Year Data Shows Intismeran Autogene + KEYTRUDA Reduces Melanoma Recurrence Risk by 49%

Merck's KEYTRUDA Plus Padcev Receives Positive EU CHMP Opinion for Muscle-Invasive Bladder Cancer

FDA Approves KEYTRUDA Combinations for Adjuvant Treatment in Clear Cell RCC

Upcoming milestones(1)

Merck — Keytruda

Related catalysts(17)

Merck — Keytruda

Merck — KEYTRUDA

Merck — KEYTRUDA

Merck — KEYTRUDA

Merck — KEYTRUDA

Merck — KEYTRUDA

Merck — KEYTRUDA

Merck — KEYTRUDA

Merck — KEYTRUDA

Merck — KEYTRUDA

Merck — KEYTRUDA

Merck — KEYTRUDA

Merck — KEYTRUDA

Merck — KEYTRUDA

Merck — KEYTRUDA

Merck — KEYTRUDA

Merck — KEYTRUDA

Indications

Therapeutic areas

Get signals before the market moves

Sponsor company

Mechanism of action

Recent signals(13)

Study Evaluates ePRO Follow-Up for Oncology Patients Post-Hospitalization

ComboMATCH Trial Targets Genetic Mutations in Advanced Solid Tumors

FDA Draft Guidance Aims to Reduce Animal Testing for Cancer Drugs

Lactylation-related biomarker predicts prognosis and therapy response in cutaneous melanoma

Study Reveals Risk Factors for Second Primary Cancer in Colorectal Cancer Survivors

Gene Amplification Adjacent to F3 Linked to Poor Outcomes in Pancreatic Adenocarcinoma

FDA Grants Priority Review for KEYTRUDA and KEYTRUDA QLEX in MIBC Treatment

Merck and Eisai's LITESPARK-012 Trial Fails to Meet Primary Endpoints in RCC

FDA Grants Breakthrough Therapy Designation for Calderasib in KRAS G12C-Mutant NSCLC

Merck Reports Promising Long-Term Data for KEYTRUDA and Intismeran in Oncology at ASCO 2026

5-Year Data Shows Intismeran Autogene + KEYTRUDA Reduces Melanoma Recurrence Risk by 49%

Merck's KEYTRUDA Plus Padcev Receives Positive EU CHMP Opinion for Muscle-Invasive Bladder Cancer

FDA Approves KEYTRUDA Combinations for Adjuvant Treatment in Clear Cell RCC

Upcoming milestones(1)

Merck — Keytruda

Related catalysts(17)

Merck — Keytruda

Merck — KEYTRUDA

Merck — KEYTRUDA

Merck — KEYTRUDA

Merck — KEYTRUDA

Merck — KEYTRUDA

Merck — KEYTRUDA

Merck — KEYTRUDA

Merck — KEYTRUDA

Merck — KEYTRUDA

Merck — KEYTRUDA

Merck — KEYTRUDA

Merck — KEYTRUDA

Merck — KEYTRUDA

Merck — KEYTRUDA

Merck — KEYTRUDA

Merck — KEYTRUDA

Indications

Therapeutic areas

Get signals before the market moves